Literature DB >> 3799692

Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma.

D A Katzka, J C Reynolds, S H Saul, A Plotkin, C A Lang, A Ouyang, S Jimenez, S Cohen.   

Abstract

Gastroesophageal reflux is well documented in scleroderma, but the complications of Barrett's metaplasia and adenocarcinoma are not well described. The records of 75 patients with scleroderma seen over a four-year period at the Hospital of the University of Pennsylvania were retrospectively reviewed to determine the prevalence of Barrett's metaplasia and adenocarcinoma of the esophagus and to identify clinical, manometric, laboratory, or radiographic criteria that might predict the presence of these lesions. Twenty-four of these patients underwent endoscopy. In this group, the prevalence of Barrett's metaplasia was 37 percent (nine patients) and adenocarcinoma was also present in two of these patients. The patients with and without Barrett's metaplasia were similar in age (range, 22 to 64 compared with 28 to 79, respectively), sex (six of nine compared with 12 of 15 female, respectively), frequency of esophageal motility disorders, presence of proximal skin involvement, digital ulceration, and pulmonary involvement as measured by diffusion capacity. Barrett's metaplasia was diagnosed on the basis of double-contrast esophagographic results in only one of eight patients with Barrett's metaplasia so-studied. Patients with Barrett's metaplasia tended to have longer duration of heartburn (90 +/- 40 months compared with 11 +/- 35 months) and dysphagia (39 +/- 22 months compared with 7 +/- 3 months). Patients with Barrett's metaplasia also tended to have greater impairment of lower esophageal sphincter pressure either at end-expiration (4.0 +/- 2.1 compared with 6.1 +/- 1.8 mm Hg) or mid-respiration (13.0 +/- 3.0 compared with 16.9 +/- 2.5 mm Hg). Using chi-square analysis, however, none of these differences reached statistical significance. Discrimination did occur on the basis of the presence of the CREST (calcinosis, Raynaud's phenomenon, esophageal manifestations of scleroderma, sclerodactyly, and telangiectasis) variant (55 percent compared with 7 percent, p less than 0.01), a duration of dysphagia of more than five months (p less than 0.03), and mid-respiratory lower esophageal sphincter pressure of less than 10 mm Hg (p less than 0.05). It is suggested that: Barrett's metaplasia of the esophagus occurs in one third of patients with scleroderma; clinical, manometric, laboratory, and radiographic features are poor predictors of the presence of Barrett's metaplasia; patients with CREST syndrome, prolonged dysphagia, or a very low lower esophageal sphincter pressure may have an increased risk for the development of metaplasia; patients with scleroderma and Barrett's metaplasia have an increased risk of complications such as stricture or adenocarcinoma.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3799692     DOI: 10.1016/0002-9343(87)90376-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature.

Authors:  David P Horowitz; Balazs Halmos; John Poneros; Joshua Sonett; Helen Remotti; Ryan J Burri
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.

Authors:  D Jaspersen
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

3.  Scleroderma and malignancy: an epidemiological study.

Authors:  A K Rosenthal; J K McLaughlin; M S Linet; I Persson
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

4.  Barrett's esophagus in scleroderma: increased prevalence and radiographic findings.

Authors:  M P Recht; M S Levine; D A Katzka; J C Reynolds; S H Saul
Journal:  Gastrointest Radiol       Date:  1988

Review 5.  Scleroderma esophagus.

Authors:  S R Fulp; D O Castell
Journal:  Dysphagia       Date:  1990       Impact factor: 3.438

6.  Tailoring Therapy for Achalasia.

Authors:  Joel E Richter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-05

7.  Esophageal bacteria and Barrett's esophagus: a preliminary report.

Authors:  Glenn L Osias; Matthew Q Bromer; Rebecca M Thomas; David Friedel; Larry S Miller; Byungse Suh; Bennett Lorber; Henry P Parkman; Robert S Fisher
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 8.  Dysphagia in dermatologic disease.

Authors:  R Bübl; B Schön
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

Review 9.  Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.

Authors:  H J Stein; J R Siewert
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

10.  Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls.

Authors:  B I Hirschowitz
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.